JP Morgan Initiates Bioline RX With Market Outperform

JP Morgan initiated coverage on

with a Market Outperform rating. The target price for Bioline RX is set to $5. Bioline RX shares have dropped 4.17 percent over the past 52 weeks, while the S&P 500 index has gained 7.51 percent in the same period. Bioline RX shares gained 4.34 percent to $2.16 in pre-market trading.